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Activation of the complement system by IgA has been a controversial subject since 
Ishizaka et al. (1) and South et al. (2) observed that C1 was not fixed by IgA. Lack of 
complement activation has also been inferred  from reports that  secretory IgA anti- 
bodies  were  unable  to  opsonize  or  promote  bacterial  killing  in  the  presence  of 
complement  (3  6).  On  the  other  hand,  there  is  evidence  that  some complement- 
dependent functions occur in the presence oflgA antibodies. Adinolfi et al. (7) showed 
that Escherichia coli could be lysed by complement in the presence of secretory IgA and 
lysozyme. Knop et al.  (8)  and Henson et al.  (9)  demonstrated stimulation of phago- 
cytosis by neutrophils  in  the  presence  of IgA and  complement.  After  "interfacial" 
aggregation, secretory IgA was able to consume C3-9 without  fixing CI; removal of 
the secretory component together with the Fc portion of the molecule did not alter 
the  mode or extent  of complement consumption  (10).  Also,  chemically aggregated 
IgA myeloma proteins and their fragments have been reported to activate complement 
by both the classical and alternative pathways  (11-15).  However, only one previous 
study has demonstrated activation of complement by IgA myeloma proteins acting as 
antibodies  (16).  In  this  study  solubilization  of immune  complexes  prepared  with 
unfractionated mouse ascites fluid induced by antigen-binding myelomas was used as 
an indirect measure of activation of the alternative pathway in mouse and guinea pig 
serum. 
Activation of the alternative complement pathway by IgA has also been suggested 
in some clinical situations.  Soter et al.  (17)  reported a  patient with IgA cryoglobuli- 
nemia  who  showed  low  levels  of C3  and  factor  B  (also  known  as  C3  activator) 
concurrent  with  their  increased  catabolism.  By immunofluorescence,  IgA, C3,  and 
factor  B  have  been  detected  at  the  dermal-epidermal junction  in  patients  with 
dermatitis  herpetiformis  (18)  and  in  the  glomeruli  in  Berger's  disease  (19).  Early 
complement components were not observed in either case. 
Although  some of the  results  in  the above experimental studies  could  have been 
due to contamination of IgA with other classes of immunoglobulins, the presence of 
complement components in secretions (20-23) where IgA is the primary immunoglob- 
ulin  (24)  could be taken to suggest  the possibility of interaction.  The present  work 
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deals  with  the  interaction  in  vitro  of  serum  complement  and  a  purified  mouse 
myeloma  IgA  protein  with  specific  antigen-binding  capacity.  The  use  of such  a 
protein as antibody both minimizes contamination with other classes of immunoglob- 
ulins and allows formation of antigen-antibody complexes, which are likely to be more 
relevant  to  natural  immune  phenomena  than  artificially aggregated  myeloma pro- 
teins. 
Materials and  Methods 
Buffers.  Borate-buffered  saline,  pH  8.0  (BBS), I  and  phosphate-buffered  saline,  pH  7.4 
(PBS), were used for chromatography and gel filtration, and barbital buffer, pH 8.6, was used 
for Pevikon  block electrophoresis for the  purification of the  IgA. Chromatography and  gel 
filtration buffers contained 0.02% NAN3. Gelatin-veronal-buffered  saline, pH 7.5, 0.145 M NaC1 
containing 0.015  M  CaCI2 and 0.005  M  MgCI2  (GVB++);  dextrose-gelatin-veronal-buffered 
saline, pH 7.5, 0.075  M  NaC1 containing 0.015  M  CaC12 and 0.005  M  MgCI2 (DGVB++); and 
0.01  M or 0.04 M  EDTA-GVB, pH 7.5, 0.145  M  NaCI were prepared according to established 
methods (25, 26) and used for complement titrations. 
Materials.  Sepharose 6B and 4B and protein A-Sepharose were obtained from Pharmacia 
Fine Chemicals  (Div.  of Pharmacia  Inc.,  Piscataway,  N. J.).  Pevikon  was  purchased  from 
Accurate Chemical  &  Scientific Corp.  (Westbury,  N.  Y.).  p-Nitrophenylphosphorylcholine 
(Biosearch, San Rafael, Calif.) and palladium-on-charcoal catalyst (Gallard-Schlesinger  Chem- 
ical Mfg. Corp., Carle Place, N. Y.) were used for the synthesis of reactive phosphoryleholine 
(PC)  hapten.  PC-CI, used  for specific elution of the myeloma protein, was  purchased  from 
Calbiochem-Behring Corp.  (American  Hoechst  Corp.,  San  Diego, Calif.).  Agarose used  in 
immunoelectrophoresis and crossed immunoelectrophoresis (CIEP) was from Behring Diagnos- 
tics  (Somerville, N. J.).  Dithiothreitol  (DTT)  and  iodoacetamide (IAA)  (both  from  Sigma 
Chemical  Co.,  St.  Louis,  Mo.)  were  used  for  reduction  and  alkylation for sodium  dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Electrophoresis grade SDS and acryl- 
amide were from Bio-Rad Laboratories (Richmond, Calif.). Bovine serum albumin (BSA) was 
purchased from Miles Laboratories, Inc.  (Elkhart, Ind.) and pooled normal guinea pig serum 
for Pel-Freez Biologicals (Rogers, Ariz.), Reagent grade KSCN and NH4OH were from Fisher 
Scientific Co.  (Pittsburgh, Pa.). BALB/c mice (6-8 wk old) were from Charles River Labora- 
tories, Inc.  (Wilmington, Mass.) and rabbits from Camm  Research Lab Animals (Wayne, N. 
J.). Pristane, used for priming the mice before intraperitoneal injection of tumor cells to produce 
ascites, was from Aldrich Chemical Co.  (Milwaukee, Wis.). Complete Freund's adjuvant  for 
immunization of mice and rabbits was from Difco Laboratories (Detroit, Mich.). Anti-guinea 
pig C3  was  purchased  from  N.  L.  Cappel  Laboratories, Inc.  (Cochranville, Pa.),  and  anti- 
guinea pig factor B was a gift from Dr. V. Nussenzweig, New York University Medical Center. 
Na125I was  from Amersham Corp.  (Arlington Heights, Ill.). Lactoperoxidase was  purchased 
from  Worthington  Biochemical Corp.  (Freehold, N. J.)  and  hydrogen  peroxide from  Fisher 
Scientific Co. 
Preparation  of PC-BSA  and  Sepharose  Conjugates.  p-Diazoniumphenylphosphorylcholine was 
synthesized  from  p-nitrophenylphosphorylcholine (27)  and  used  to  prepare  PC-Sepharose 
immunoadsorbent  (27)  and  PC-BSA  (28)  with  three  to  five PC  groups  per molecule BSA, 
calculated by the method of Gearhart et al. (29). 
Antisera.  Antisera to mouse a, #, and y chains were from McWilliams et al.  (30).  Rabbit 
antiserum  to  BSA  was  prepared  by  immunizing  rabbits  with  BSA  in  complete  Freund's 
adjuvant in the footpads and giving regular boosters intradermally with BSA in saline. BALB/ 
c  mouse anti-BSA was prepared by injecting female mice (6-8 wk old) with 500 #g BSA in 
i Abbreviations used in this paper." BSA, bovine serum albumin;  BBS, borate-buffered saline; CIEP, crossed 
immunoelectrophoresis; C4DGPS, C4-deficient guinea pig serum; DTT, dithiothreitol;  EA, sheep eryth- 
rocytes coated  with  antibodies  to sheep erylhrocytes;  factor  H,  ylH  globulin;  factor  I,  formerly C3b 
inactivator;  IAA, iodoacetamide; NGPS, normal guinea pig serum; 125I-C3gP-NGPS,  NGPS trace-labeled 
with 1251-C3~; NHS, normal human serum; oxy C2, oxidized human C2; PBS, phosphate-buffered saline; 
PC, phosphorylcholine; SDS-PAGE, sodium dodecyl sulfate-gel electrophoresis. (Complement nomencla- 
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complete Freund's adjuvant in the footpads and bleeding 4 wk later (31). Rabbit anti-sheep 
and  anti-bovine erythroeytes  were  prepared  according  to  Campbell et  al.  (32).  The  50% 
saturated  (NH4)2SO4 precipitation fraction of anti-sheep erythroeyte antiserum was  used to 
prepare sheep erythroeytes coated with antibodies to sheep erythroeytes (EA) for complement 
titrations (see below). 
Complement Reagents and  Complement Titrations.  C4-deficient guinea pig serum  (C4DGPS) 
obtained from our own colony was pooled after C4 activity was checked in the individual sera. 
Human serum was obtained from normal donors and pooled. Blood from male BALB/c mice 
was  drawn into 5 mM E-aminocaproic acid, centrifuged, and the pooled serum used as  the 
source of mouse complement. 
Human and guinea pig C1, C2, and C4, and oxidized human C2 (oxy C2)  were prepared 
from human and guinea pig sera (33-35). Guinea pig C3 was purified from pooled, freshly 
drawn guinea pig serum to which diisopropylfluorophosphate (Calbiochem), phenylmethylsul- 
fonylfluoride, and benzamidine (Sigma Chemical Co.)  were added to inhibit proteolysis.  The 
serum was passed  through a  lysine-Sepharose column (Pharmacia Fine Chemicals) (36) and 
the C3 was purified by the method of Nelson et al.  (33), except that at each step inhibitors of 
proteolysis  were added (DFP, PMSF, benzamidine). C3  gp purified by this method was hemo- 
lytically active and gave in SDS-PAGE a single band at 180,000 mol wt that yielded two bands 
upon reduction, 115,000 mol wt (C3a)  and 64,000 mol wt (C3fl). The C3 was labeled with 125I 
by lactoperoxidase (37). There was minimal loss of hemolytic activity and the specific activity 
was 6.25 x  108 cpm/mg. When labeled C3  gp was reduced, electrophoresed in 5-15% gradient 
acrylamide SDS slab gels, and autoradiographed on Kodak XR-5 film (Eastman Kodak Co., 
Rochester,  N.  Y.),  the  a  chain was  labeled more strongly than  the fl chain; trace-labeled 
contaminants that did not stain with Coomassie Blue appeared at 72,000 and 50,000 tool wt. 
Guinea pig C5 was purchased from Cordis Laboratories, Inc. (Miami, Fla.). Reagents deficient 
in C5 (R5) and C3 (R3) were prepared by treatment of NGPS with KSCN or NH~ (38-40). 
Titrations of whole complement (CH50) and C3-9, both human and guinea pig, were done 
according to Kabat and Mayer (25) and Rapp and Borsos (26). Mouse C3-9 were titrated with 
EAClhU4hu2  °"y prepared with purified components. Human and guinea pig C4 were titrated 
with EA and C4DGPS  (41). Titration of mouse C4 was carried out with EA prepared with 
bovine erythrocytes and antibody, C4DGPS, and oxy C2 (42). Human C3 and guinea pig C3 
and C5 were measured with EAClhU4  hu and EAClg°4  gv (43) with oxy C2  h~ or C2  gp, respectively, 
and reagents deficient in the corresponding component. Factor B as antigen was measured by 
CIEP on 50 ×  50-mm glass plates (44). 
SDS-PAGE.  Electrophoresis for assessing the purity of the mouse IgA was done in cylindrical 
5.0% gels in 0.1 M Tris acetate, pH 7.4, with 0.02 M EDTA and 1% SDS. Slab gel electrophoresis 
was  performed  according  to  Laemmli  (45), and  two-dimensional slab  gel  electrophoresis 
according to Law and Levine (46). Hydroxylamine treatment of gel strips was done according 
to Law et al. (47). 
Preparation of Immune Complexes.  IgA  and  IgG  immune complexes  were  prepared  near 
equivalence as determined by precipitin curve analysis (48). Because the IgA myeloma protein 
is  a  low  affinity antibody, the  equivalence zone was  broad.  The  midpoint was  taken  as 
equivalence. 
Purification of TEPC-15 IgG Myeloma Protein.  106 TEPC-15 tumor cells were injected intra- 
peritoneally into 6-8-wk-old BALB/c mice. After 14-18 d ascites fluid and serum were collected, 
pooled, and stored at --20°C. 
The IgA myeIoma protein was purified by a modification of the method of Chesebro and 
Metzger (27). Serum or ascites fluid was dialyzed against BBS, pH 8.0, diluted 1:3 in BBS, and 
passed over a PC-Sepharose immunoadsorbent  column. After washing, PC-specific protein was 
eluted with 0.001 M PC-CI in BBS, concentrated by ultrafiltration, dialyzed against PBS, pH 
7.0, and then passed over a calibrated Sepharose 6B column to separate the IgA into monomeric, 
dimeric,  and  polymeric fractions.  The  dimeric  fraction was  passed  through  a  protein A- 
Sepharose column to remove any contaminating IgG (49) and through an anti-# Sepharose 
column to remove any contaminating  IgM. The resultant dimeric IgA was free of contaminating 
proteins as assessed by immunoelectrophoresis  and SDS-PAGE under reduced and nonreduced 
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dimeric IgA was the most abundant form and is the one most closely related to secretory  IgA, 
the primary antibody of secretions,  it was used in the experiments  to be presented.  A  limited 
number  of experiments  were  also  performed  with  polymeric  and  monomeric  IgA,  and  the 
results were similar to those with dimeric IgA. However, monomeric IgA activated complement 
less efficiently. 
Results 
Activation of the  Complement System by  Dimeric IgA  Anti-PC-BSA  Immune Complexes. 
Initial  analysis of complexes prepared  with the IgA  myeloma and PC-BSA  showed 
that maximum consumption of C3 in NGPS occurred near equivalence. To determine 
whether  IgA  complexes  at  equivalence  consumed  other  complement  components. 
suspensions of IgA immune complexes were mixed with equal volumes of guinea pig, 
mouse, or human serum and incubated at 37°C.  The complexes were then removed, 
and  the  residual  activities  of  the  supernatants  titrated.  IgA  immune  complexes 
consumed 40%  of the  hemolytic  activity  of C3-9  in  guinea  pig  serum  and  30%  in 
mouse serum (Table  I). The controls showed no complement consumption. The loss 
of hemolytic activity in guinea pig serum was associated with a 47% reduction in C3 
activity without loss of C4 or C2 activities.  That  the C3 consumption in NGPS  was 
indeed due to activation by IgA immune complexes was demonstrated by CIEP with 
an anti-C3 gp antiserum, which showed the characteristic shift  in mobility of C3 to a 
more anodal position  (data not shown). When human serum was used as the source 
of complement,  none  was  consumed.  This  findings  could  not  be  explained  by  a 
general incompatibility between mouse immunoglobulins and normal human serum 
(NHS)  as evidenced  by the capacity of mouse IgG  anti-BSA  immune complexes  to 
activate  human  complement  (Table  I).  Because  of  limitations  in  techniques  for 
measuring individual components of complement in mouse serum and the observation 
that immune complexes prepared with mouse immunoglobulins activated guinea pig 
complement  as  well  as  mouse  complement,  guinea  pig  complement  was  used  for 
further experiments. 
TABLE  I 
Complement Consumption by IgA and IgG Immune Complexes 
in  Various Sera* 
Ig class  Source of serum 
Percent complement consumption 
C3-9  C4  C2  C3 
IgA  Guinea pig  40  0  0  47 
Mouse  30  0  ND:~  ND 
Human  0  0  0  0 
Guinea pig  100  59  45  94 
Mouse  16  t 00  ND  ND 
Human  36  35  74  ND 
* 0.2-ml samples  each of a suspension  of IgA-anti-PC-BSA or IgG-anti-BSA 
immune complexes at a concentration  of 2 mg antibody/ml (plus controls of 
dimeric  IgA  alone [2  mg/ml], PC-BSA [0.1  mg/ml], or saline)  were  mixed 
with  an  equal  volume  of  undiluted  NGPS,  mouse  serum,  or  NHS  and 
incubated at 37°C, with shaking, for 1 h. The samples were then chilled in 
ice, the complexes removed  by centrifugation,  and the residual  complement 
activities  of the supernatant  sera measured. 
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The lack of C4 and C2 utilization shown in Table I suggested that consumption of 
hemolytic C3 by IgA immune complexes  takes place via the alternative pathway of 
complement activation. Further evidence was obtained in experiments that demon- 
strated depletion of factor B in both NGPS and C4DGPS, a source of complement in 
which only the alternative pathway is available. The IgA complexes consumed ~50% 
of the  factor B  and  C3,  and  essentially  no  C5  (Table  II  and  Fig.  1).  A  sample 
incubated with zymosan showed  53%  depletion of C3  hemolytic activity and  70% 
depletion of factor B antigen.  In  contrast  to the lack of C5  consumption by IgA 
complexes, zymosan activated 29% of the C5. Similar results were obtained in NGPS, 
except that the availability of the classical pathway allowed more efficient activation 
by zymosan (90% of the factor B and  100% of the hemolytic C3)  whereas the IgA 
activation remained the same as in C4DGPS (not shown). These results demonstrate 
differences  in alternative pathway activation between IgA immune complexes  and 
zymosan. Furthermore, they illustrate the contribution of the classical  pathway in 
complement activation by zymosan but not by IgA. 
Time, Temperature, and Ion Requirements for Activation of Guinea Pig Complement by IgA 
Immune Complexes.  To determine the time required to achieve maximum C3 activa- 
tion, IgA immune complexes and NGPS were incubated at 37°C. Samples were taken 
TABLE  II 
Activation of the Alternative Pathway by IgA Immune Complexes 
and Zymosan in C4DGPS* 
Percent consumption 
B  C3  C5 
IgA complexes  50  48  9 
Zymosan  70  53  29 
Control  0  0  0 
* 0.2  ml of C4DGPS was incubated at  37°C  for  1 h  with equal volumes of 
either  a  suspension of IgA immune complexes at  0.5  mg antibody/ml, a 
suspension  of  0.5  mg/ml  of  zymosan,  or  saline.  Factor  B  antigen  was 
measured by CIEP; C3 and C5 activities were measured hemolytically. 
FIc.  1.  Depletion of factor B in NGPS by mouse IgA immune complexes and zymosan measured 
by CIEP.  0.2  ml of NGPS was incubated  with 0.2  ml of IgA complexes (0.5  mg/ml), 0.2  ml of 
zymosan  (0.5  mg/ml), or  0.2  ml  of saline  for  1 h  at  37°C.  After centrifugation,  5  /zl  of each 
supernatant was loaded into a well in  1.2% agarose gel for 2 h of electrophoresis at 200 V in EDTA- 
barbital buffer, pH 8.6. At the end of the first dimension, the excess agarose was cut off and 2.6 ml 
of agarose containing  10 /tl  of anti-GP  factor B  antiserum was poured onto the plate.  A  second 
electrophoresis was run overnight (50 V) perpendicular to the first.  The plates were then washed, 
dried, and stained with Coomassie Blue to reveal the precipitation peaks. Transferrin-anti-transferrin 
(TF) was included as a mobility marker in each slide. 236  ACTIVATION OF COMPLEMENT  BY  IgA IMMUNE  COMPLEXES 
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Fz~.  2.  Time-course  of C3 activation in NGPS by IgA immune complexes. 0.6 ml of IgA anti-PC- 
BSA immune complexes at 0.5 mg antibody/ml was mixed with 0.6 ml of NGPS. Equal volumes  of 
saline and NGPS were also mixed and incubated at 37°C as a control. Samples were incubated at 
three different temperatures. At the given times, 0.2-ml samples were removed, diluted with 0.8 ml 
ice cold GVB  ÷÷, and centrifuged. The residual C3 hemolytic activities of the supernatants were 
titrated. O, C3 consumed at 37°C; A, at 0°C, and/k, at 17°C. 
TABLE  III 
Cation Requirements  for C3-9 Consumption by IgA Immune Complexes in 
Guinea Pig Serum  * 
Serum treatment  Percent C3-9 consumption 
Saline  30 
EGTA + Mg  ÷÷  36 
EDTA  0 
* To 0.2 ml of NGPS, made 0.02 M  in EGTA and 0.002 M  in MgCI2, or 0.01 
M  in EDTA, was added 0.2 ml of a suspension of IgA immune complexes at 
0.5 mg antibody/ml. After  1 h  at 37°C the C3-9 hemolytic activities of the 
supernatant sera were measured. 
at  intervals and  the  residual  C3  hemolytic activities of the  supernatant sera  were 
compared  with  the  saline  control.  After  20  min  of  incubation, -45%  of the  C3 
hemolytic activity had been depleted and no further consumption was observed (Fig. 
2). When the reaction was performed at  17°C or 0°C  (even up to  16 h), no C3 was 
utilized. Guinea pig C3-9 was consumed in the presence of EGTA and Mg  ++, but not 
in EDTA, indicating that Mg  ++ but not Ca  ++ is required (Table III). 
Complement  Activation  as a Function  of Immune Complex  Dose.  Experiments were next 
performed  to  examine in more  detail  the  effect  of different doses  of IgA and  IgG 
immune complexes on C3 and C5 in both NGS and C4DGPS. Suspensions of varying 
concentrations of immune complexes were incubated with equal volumes of undiluted 
NGPS or C4DGPS. The residual C3 and C5 hemolytic activities of the supernatant 
sera were measured. Increasing C3 consumption by IgA immune complexes occurred 
in both NGPS and C4DGPS, reaching a  maximum of 40-50%  (Fig. 3).  In contrast, 
C3 consumption approaching 100% was observed with the IgG immune complexes in 
NGPS  (Fig. 3 A).  However, when C4GDPS was used, the pattern of utilization was 
the same as that obtained with IgA immune complexes (Fig. 3 B). Complexes prepared 
with IgA were unable to consume substantial C5 activity in either NGPS or C4DGPS 
(Fig. 4). However, activation of C5 by IgG complexes in NGPS displayed the expected PFAFFENBACH,  LAMM,  AND  GIGLI  237 
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Fzo. 3.  Activation of C3 by immune complexes. 0.2 ml of IgA anti-PC-BSA immune complexes or 
IgG anti-BSA immune complexes prepared at equivalence at the given concentrations were mixed 
with an equal volume of either NGPS or C4DGPS and incubated  at 37°C for 1 h. 0.2 ml of saline 
was incubated  with an equal volume of either serum as controls. The residual hemolytic activities 
of the supernatant sera were measured after centrifugation.  Each curve indicates a representative 
experiment: O, IgG complexes; O, IgA complexes. Brackets depict the range of C3 activation  in 
different experiments with the IgA immune complexes. 
dose-dependent consumption (Fig. 4 A). Similar to the alternative pathway activation 
by  IgA  immune  complexes,  IgG  immune  complexes  were  unable  to  diminish  C5 
activity when  only  the  alternative  pathway  was  available  (Fig.  4 B).  In  this  case, 
alternative pathway activation by IgA and IgG immune complexes was limited to C3 
and resulted in a maximum of 50% C3 consumption, even with 2.0 mg/ml of immune 
complexes. 
To investigate whether the limited C3 consumption  by IgA complexes was due to 
insufficient functional convertase-binding sites on the complexes, the following exper- 
iment  was  performed.  A  suspension of IgA immune  complexes was  incubated  with 
NGPS.  After incubation, the supernatant  fluid was separated and the hemolytic C3 
activity found  to be 53%  consumed  (Table IV). When  the complexes removed from 
the original reaction mixture were suspended in fresh NGPS, C3 was activated to the 
same  extent  as  in  the  initial  serum  (47%  C3  consumed).  Since  the  IgA  immune 
complexes retained their capacity to activate C3, it was considered that activation of 
the residual C3  in the supernatant  serum was impaired. Therefore,  the supernatant 238  ACTIVATION OF  COMPLEMENT  BY  IgA  IMMUNE COMPLEXES 
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FIG. 4.  Activation of C5 by immune complexes. 0.2 ml of IgA anti-PC-BSA immune complexes or 
IgG anti-BSA immune complexes prepared at equivalence at the given concentrations were mixed 
with an equal volume of either NGPS or C4DGPS and incubated at 37°C for 1 h. 0.2  ml of saline 
was incubated with an equal volume of either serum as controls. The residual hemolytic activities 
of the supernatant sera were measured after centrifugation. Each curve indicates a  representative 
experiment: C),  IgG complexes; O, IgA complexes. Brackets depict  the range of C5  activation  in 
different experiments with the IgA immune complexes. 
of the original reaction mixture was divided into three equal samples that were added 
to  fresh  IgA  immune  complexes,  fresh  IgG  immune  complexes,  or  saline.  These 
samples  were  incubated,  the  complexes removed,  and  the  residual  hemolytic C3 
activity measured. Fresh IgA immune complexes failed to activate C3 further, whereas 
fresh IgG complexes completely consumed the remaining C3 activity (Table IV). 
This further consumption of C3 by IgG could be explained by activation of either 
the  classical  or  alternative pathways.  This  question  was  investigated  in  the  next 
experiment. IgA immune complexes were incubated with C4DGPS and  the super- 
natant divided into equal samples that were reincubated with suspended pellets of 
fresh IgA or IgG immune complexes or zymosan. In the C4DGPS supernatant, neither 
fresh  IgA nor IgG complexes could further activate factor B, C3, or C5  (Table V). 
Only zymosan utilized these components in C4DGPS supernatant.  The complexes 
from the original mixture ("activated" IgA complexes) were treated as in the previous 
experiment, and the results were similar (Table V). PFAFFENBACH, LAMM,  AND  GIGLI  239 
TABLE  IV 
Ability of lgA Complex-Activated NGPS to be Further Activated 
by Subsequent Treatment * 
First stage  Second stage 
Percent  PercentS:  Treatment of  Treatment of  C3 con-  C3 con-  fresh NGPS  activated NGPS  sumption  sumption 
Fresh IgG complexes  53  Saline  0 
Activated IgA complexes  47  Fresh IgA comptexes  0 
Fresh IgG complexes  tOO 
* 0.4 ml of fresh NGPS was incubated with 0.4 ml of 0.5 mg/ml IgA immune 
complexes  for  1 h  at  37°C.  After centrifugation, 0.3-ml  aliquots  of the 
supernatant  were  incubated with  fresh  pellets  of the  indicated  immune 
complexes equivalent to 0.15 ml of 0.5 mg/ml complexes for another hour at 
37°C.  The  remaining supernatant was carried as  the saline  control. The 
equivalent of 0.2 ml of 0.5 mg/ml of the activated IgA immune complexes 
was incubated at the same time with fresh NGPS.  Residual C3 activities  of 
the resulting supernatant sera were measured hemolytically. 
Percent of the 47% residual C3 activity of the first supernatant. 
TABLE  g 
Ability of IgA Complex Activated C4DGPS to be Further Activated 
by Subsequent Treatment * 
First stage  Second stage 
Percent  Percent 
Treatment of  consumption  Treatment of acti-  consumptionS: 
fresh C4DGPS  vated C4DGPS 
B  C3  C5  B  C3  C5 
Fresh  IgA  corn-  50  48  9  Saline  0  0  0 
plexes 
Activated IgA  41  50  3  Fresh IgA complexes  0  0  7 
complexes 
Fresh IgG complexes  0  2  9 
Zymosan  1OO  52  30 
* 0.5 ml of C4DGPS were  incubated for  1 h at  37°C with 0.5 ml of IgA immune 
complexes  at 0.5 mg/ml. After centrifugation, 0.2 ml aliquots of the supernatant 
were  mixed and incubated with saline  or pellets  of the equivalents of 0.1  ml of 
either  IgA  immune  complexes,  IgG  immune  complexes,  or  zymosan,  all  at  a 
concentration of 0.5 mg/ml, for  l  h at 37°C.  0.2 ml of the resuspended activated 
IgA complex pellet was mixed and incubated at the same time with fresh C4DGPS. 
Residual C3  and C5  activities  of the resulting supernatant sera were measured 
hemolytically;  factor B antigen was measured by CIEP. 
:~ Of the residual activities of the first supernatant. 
Binding  of tzSI-C3a"  to  Immune  Complexes.  Because  binding  of C3b  to  a  suitable 
surface may be required for efficient C3/C5  alternative pathway  convertase activity, 
it  was considered that  the IgA immune  complexes might  not supply such a  surface 
and that therefore alternative pathway  activation was limited. To determine whether 
C3 binds to the IgA complexes during complement activation, 125I-C3gP was added to 
NGPS  to  trace  label  the C3.  IgA  or  IgG  immune  complexes were  mixed  with  an 
equal volume of tzSI-C3gP-NGPS and the reactions carried out as described previously. 
The  precipitates were washed until  the wash buffer counts reached background. To 240  ACTIVATION  OF  COMPLEMENT  BY  IgA  IMMUNE  COMPLEXES 
TABLE  VI 
Binding of 125/-C3g'P to Immune Complexes  * 
IgA  IgG 
complexes  complexes 
Percent counts per minute bound  0.5  5.9 
Percent C3 activated  40.6  80.8 
* To 0.2-ml samples of 125I-C3~-NGPS, 0.08 ml of 0.2 M EDTA or 0.08 ml of 
GVB  +÷ was added in the cold. Then 0.2 ml of immune complexes at 0.5 mg 
antibody/ml was  added and the mixtures incubated at  37°C  for  l  h  with 
shaking. Each tube was  counted to determine the total counts per minute 
(cpm)  added. The percent cpm bound to the washed precipitates in EDTA 
was subtracted from the percent cpm bound to the precipitates in the absence 
of EDTA to yield the percent cpm bound to the precipitates due to activation. 
C3 activation was measured by hemolytic titration. 
FIG.  5.  Binding of 125I-C3gP to immune complexes.  After incubation in NGPS to which leVI-C3  ~° 
had been added, immune precipitates were solubilized in SDS, reduced with DTT, and run on an 
SDS 5-15% polyacrylamide slab gel. An equal amount of radioactivity was loaded in each track. 
Autoradiography of the dried  gels  was  then  performed.  Track  1,  IgA complexes;  track  2,  IgA 
complexes in the presence of EDTA (no complement activation); track 3, IgG complexes; track 4, 
IgG complexes in the presence of EDTA; track 5, :2~I-C3gV  in NGPS and EDTA showing differential 
labeling of a  and fl chains. Molecular weights are indicated on the left. The slowest  band (mol wt 
±  165,000) in track 3 is interpreted as a covalent combination of the y chain of IgG and the a chain 
of C3. 
measure  nonspecific binding, a  control sample of t2SI-C3gP-NGPS was incubated  with 
0.04  M  EDTA  before  addition  of  the  immune  complexes  to  prevent  complement 
activation. The  IgG immune  complexes added  to the :zsI-C3g°-NGPS  activated  twice 
the  amount  of C3  but  bound  12  times  more  C3  than  the  IgA  immune  complexes 
(Table VI). 
The  nature  of the binding  of :2~I-C3gP to  the  immune  precipitates  was  studied  by 
autoradiography  of polyacrylamide  slab  gels  in which  samples  of the  washed,  SDS- 
solubilized, reduced  precipitates had  been electrophoresed  (Fig. 5). There  is a  band  of PFAFFENBACH, LAMM, AND GIGLI  241 
FIG. 6.  Two-dimensional electrophoresis of solubilized IgG complexes with bound 125I-C3~°.  After 
eleetrophoresis of the solubilized, reduced IgG complexes with bound  125I-C3gP  in an SDS 5-10% 
polyacrylamide gel, a strip was cut out, treated with 1 M hydroxylamine, and reduced with DTr 
a second time. This strip was then placed on top of an SDS 5-15% gradient polyacrylamide gel and 
electrophoresed along with a sample of the original material not exposed to hydroxylamine and 
containing the same number of counts (shown vertically on the left). Locations of some C3 products 
are indicated; others cannot be precisely identified. 
165,000 mol wt in the case of IgG complexes (track 3). No comparable high molecular 
weight band is seen with the IgA complexes (track  1). The 165,000 mol wt band could 
correspond to the T chain of IgG (55,000 tool wt)  covalently bound to the labeled a' 
chain  of C3  (115,000  mol  wt).  Thus,  it  appears  that  classical  pathway  activation 
results  in  binding  of C3  gp  to  the  IgG  immune  complexes,  whereas  IgA  immune 
complex  activation  of the  alternative  complement  pathway  does  not  lead  to stable 
binding of C3. 
Since the putative bond between the a  chain of C3 and the ,/chain of IgG was not 
sensitive to DTT, the possibility of an ester linkage was considered. After electropho- 
resis,  the gel was treated  with  hydroxylamine and  then with  reducing sample buffer 
(47) to attempt to cleave the proposed link. A second electrophoresis perpendicular to 
the first dimension was then performed. The 165,000-mol wt spot, after hydroxylamine 
treatment  and  reduction,  upon electrophoresis  in  the second dimension  gave rise  to 
some  radioactive  material  of 66,000  mol  wt  (Fig.  6).  Because  this  is  slightly  larger 
than the C3  go/~ chain and is strongly labeled, whereas the C3  gp/~ chain does not label 
efficiently (cf. Fig. 5, track 5), the 66,000 mol wt band is likely to be derived from the 
C3a' chain. The remaining  165,000 mol wt material  could result  either  from incom- 
plete cleavage by hydroxylamine or intact C3~x' chain bound to the y chain of IgG by 
a nonester bond. As a control for the hydroxylamine treatment,  EAC 1  t25I-C4hU ghosts 
were solubilized,  electrophoresed,  and  treated  in  the same manner  as were  the  IgG 
immune complexes (51). After electrophoresis in the second dimension,  a  radioactive 
high molecular weight spot  (C4a' that had been bound to a  cell surface protein)  was 
completely displaced to the location of C4a' chain, 90,000 tool wt  (not shown). These 
experiments  with  radioactive C3 suggest  that  efficient convertase formation requires 
covalent  binding  of C3  to a  surface.  This  binding  can  be  supplied  by the  classical 242  ACTIVATION OF COMPLEMENT BY IgA IMMUNE COMPLEXES 
pathway but neither IgA nor IgG appears to support an appropriate binding site for 
the alternative pathway. 
Discussion 
A model system using a mouse myeloma protein as antibody, complexed with the 
antigen  PC-BSA,  was  used  to  investigate activation of the complement system by 
IgA. IgA immune complexes were able to activate C3-9 in mouse and guinea pig but 
not human serum. Activation occurred via the alternative pathway as evidenced by 
lack of C4 and C2 activation in both NGPS and C4DGPS. Moreover, consumption 
of C3 by IgA immune complexes required the presence of Mg  +÷ but not Ca ++, and 
factor B, required for the formation of the alternative pathway C3 convertase (52), 
was depleted. 
Because of the limited C3-9 consumption in spite of substantial C3 activation (50%) 
by the IgA immune complexes in guinea pig serum, it was considered that  the late 
acting components C5-9 were not used. Although increasing C3 activation occurred 
to a maximum of 50% with greater doses of IgA immune complexes, C5 consumption 
remained low. Without activation and cleavage of C5, the assembly of the terminal 
components  (C5b-C9)  cannot  take  place  (53), and  total complement consumption 
remains limited. 
Because there was always +50% of the C3  activity left in the supernatant  serum 
even when very large amounts of IgA complexes were used, it was of interest to know 
whether this C3 was susceptible to further activation. The results in Tables IV and V 
demonstrate that this C3 could be consumed under certain conditions. The superna- 
tant from NGPS previously incubated with IgA complexes could be further activated 
by fresh IgG complexes (Table IV), which activate the classical pathway resulting in 
consumption  of the  residual  C3.  Whether  there  could  be  additional  alternative 
pathway  activation  in  the  supernatant  serum  was  examined  with  C4DGPS.  The 
results of these experiments demonstrate that  in the absence of a  classical pathway 
neither  the  residual  C3  activity  nor  factor  B  could  be  further  depleted  by  IgG 
complexes, and, as previously shown, IgA complexes were without effect. However, 
zymosan, an alternative pathway activator with a  "protected" surface (54,  55)  was 
capable of consuming the remaining factor B, and substantial amounts of C3 and C5. 
The action of the control proteins (factor I [formerly C3B inactivator] and factor H 
[B1H globulin])  during alternative pathway activation by IgA  immune complexes 
may be an  important  factor limiting C3  consumption. The C3  activated could be 
primarily in the fluid phase; it is quickly inactivated and therefore cannot participate 
in assembly of the C3bBb  convertase on the IgA immune complexes. Whereas the 
classical pathway has a molecule, CT, which is specifically bound to and activated by 
IgG  or  IgM  antibody-antigen  complexes  or  aggregates,  and  leads  to  consistent, 
relatively stable  C3/C5  convertase  formation,  the  alternative  pathway  convertase 
seems to be less  specific in  its binding,  and  deposition of C3  is  left much  more to 
chance. For C5 cleavage to take place it has been suggested that the C3b generated 
by either the  classical  or  alternative  pathway  convertase must  bind  to  a  suitable 
surface  and  in  turn  bind  C5  to  enable  the  C3  convertase to  acquire  C5  cleaving 
function (56).  Zymosan provides a  suitable surface for efficient alternative pathway 
activation (54,  55)  and C5 consumption whereas the IgA immune complexes do not PFAFFENBACH,  LAMM,  AND GIGLI  243 
(Table II), nor do IgG complexes in C4DGPS (Fig. 4). Without a protected surface, 
the alternative pathway is more susceptible to the actions of factors I and H. 
The complete lack of activation of complement by mouse IgA complexes in NHS 
was not a result of total species incompatibility because mouse IgG immune complexes 
were able to activate the classical pathway in NHS. Whether the lack of activation 
could be due to rigorous control remains to be investigated. 
The data presented here on the binding of radioactive C3  go to mouse IgG complexes 
during classical pathway activation further support the requirement for binding of 
activated C3 to an appropriate surface to establish efficient C3/C5 convertase function 
(Table VI). The relative lack of binding of C3 gp to the IgA complexes implies that 
this  type  of alternative  pathway  activation  is  inefficient  and  subject  to  rigorous 
control. 
In the case of the classical pathway activation of C3 byIgG complexes, the bond 
between the C3c~' chain and the y chain of IgG appears to be covalent, not disulfide 
but at least partly ester in nature because some can be dissociated by hydroxylamine 
and resolved into a C3a' fragment of 66,000 mol wt (Fig. 6). The 165,000-mol wt spot 
that remains on the diagonal should contain intact C3a' chain. It is possible that the 
part of the C3 responsible for the convertase activity remains intact and covalently 
bound to the immune complexes while the inactivated portion can be removed. Since 
IgA complexes do not bind an appreciable amount of C3, all of the C3b generated 
into the fluid phase is rapidly inactivated. 
In view of recent reports of synergism by different antibody classes in alternative 
pathway activation (57, 58), it could be considered that IgA requires the participation 
of another class of antibody to create more effective alternative pathway activation. 
However, these studies used zymosan or erythrocytes as the surface on which C3b is 
deposited. Analogy with immune complexes is difficuff because the structures avail- 
able for C3b binding are different. In the case of immune complexes, a second class 
of antibody could enhance the amplification of the alternative pathway in a manner 
similar to that proposed for solubilization (59) rather than increase the initial rate of 
C3b  deposition as has been reported for IgG antibody enhancement of alternative 
pathway activation by zymosan (57). Experiments involving cooperation by antibody 
classes in complement activation as applied to protein antigens in the form of immune 
complexes have yet to be done. 
In conclusion, activation of the alternative or classical pathways by immunoglob- 
ulins may depend on their abilities to bind C 1 and subsequently C3 in appropriate 
conformation for efficient convertase formation and function. The binding ofC 1  to 
IgG or IgM may cause a change in the antibody molecule, allowing C3b to bind. If 
the antibody does not bind C 1, as is the case for IgA, the alternative pathway may be 
activated, but without a C3b binding site the C3b in the fluid phase would be quickly 
inactivated by factors I  and  H, thereby limiting the activation.  The control of (]3 
activation in these cases might not be overcome until and unless either an appropriate 
surface is provided to stabilize the alternative pathway convertase, or the classical 
pathway can be activated. It is possible that  cooperation between immunoglobulin 
classes could fulfill either or both of these requirements. 
Summary 
Activation  of the  complement  system  by  IgA  was  investigated  with  immune 
complexes containing a mouse IgA myeloma protein with specificity for phosphoryl- 244  ACTIVATION OF COMPLEMENT BY IgA IMMUNE COMPLEXES 
choline linked to bovine serum albumin  (PC-BSA). These IgA anti-PC-BSA immune 
complexes activated  the alternative  complement  pathway  in mouse and  guinea pig 
serum,  while  human  complement  was  not  affected.  The  activation  proceeded  with 
consumption of C3 but  little or no consumption of C5.  C3 did  not bind  to the IgA 
immune complexes during complement activation although it did bind covalently to 
IgG immune complexes. It is suggested that IgA immune complexes do not supply a 
suitable surface for C3 binding and effective alternative pathway convertase assembly; 
therefore,  cleavage is  limited  and  occurs primarily  in  the  fluid phase.  Without  C3 
binding,  C5  cleavage  does  not  occur  nor  can  the  alternative  pathway  activation 
proceed to the amplification step. 
Received  for publication 20July 1981. 
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